Lisa A. Jackson, MD, MPH

Jackson_Lisa_A__205x293.jpg

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator (PI) for the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention (CDC). She is also PI of the KPWHRI Vaccine and Treatment Evaluation Unit network site—one of nine network sites that the National Institutes of Health sponsors.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

  • Vaccines & Infectious Diseases

    Vaccine  safety; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia

 

Recent publications

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2020 Dec 3:NEJMc2032195. doi: 10.1056/NEJMc2032195. [Epub ahead of print]. PubMed

Kharbanda EO, Vazquez-Benitez G, DeSilva MB, Spaulding AB, Daley MF, Naleway AL, Irving SA, Klein NP, Tseng HF, Jackson LA, Hambidge SJ, Olaiya O, Panozzo CA, Myers TR, Romitti PA. Developing algorithms for identifying major structural birth defects using automated electronic health data. Pharmacoepidemiol Drug Saf. 2020 Nov 20. doi: 10.1002/pds.5177. Online ahead of print. PubMed

Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, Williams JTB, Naleway AL, Klein NP, Hambidge SJ, Jacobsen SJ, Glanz JM, Jackson LA, Shimabukuro TT, Weintraub ES. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020 MMWR Morb Mortal Wkly Rep. 2020;69(38):1355-1359. doi: 10.15585/mmwr.mm6938e2. PubMed

Jackson LA, Roberts PC, Graham BS. A SARS-CoV-2 mRNA vaccine - preliminary report. N Engl J Med. 2020 Aug 19;383(12):10.1056/NEJMc2026616#sa3. doi: 10.1056/NEJMc2026616. PubMed

Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B; US Flu VE Network Investigators. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 Aug 12:S0264-410X(20)31032-X. doi: 10.1016/j.vaccine.2020.08.011. Online ahead of print. PubMed

Munoz FM, Patel SM, Jackson LA, Swamy GK, Edwards KM, Frey SE, Petrie CR, Sendra EA, Keitel WA. Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020;38(33):5355-5363. doi: 10.1016/j.vaccine.2020.05.059. Epub 2020 Jun 19. PubMed

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. PubMed

Hesse EM, Navarro RA, Daley MF, Getahun D, Henninger ML, Jackson LA, Nordin J, Olson SC, Zerbo O, Zheng C, Duffy J. Risk for subdeltoid bursitis after influenza vaccination: a population-based cohort study. Ann Intern Med. 2020 Jun 23. doi: 10.7326/M19-3176. [Epub ahead of print]. PubMed

Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, Gaglani M, Monto AS, Martin ET, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Patel M. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis. 2020 Jun 7:ciaa706. doi: 10.1093/cid/ciaa706. [Epub ahead of print]. PubMed

Chung JR, Flannery B, Gaglani M, Smith ME, Reis EC, Hickey RW, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Segaloff HE, Kim SS, Patel MM. Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory tract illness. JAMA Pediatr. 2020 May 4:e200372. doi: 10.1001/jamapediatrics.2020.0372. [Epub ahead of print]. PubMed

 

news

Vaccine-patient-Norman-Hulme_1col.jpg

COVID-19 vaccine generates immune response in older adults

The investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.

News

Covid-19-vaccination-trial_closeup-shot_1col.jpg

COVID-19 vaccine well tolerated, generates immune response

National Institute of Allergy and Infectious Diseases-sponsored phase 1 trial tested mRNA vaccine.

KPWHRI In the Media

Kaiser Permanente launches first coronavirus vaccine trial

Alumna is leader in COVID-19 vaccine study

W&M Alumni Magazine, Sept. 29, 2020

research

Jennifer Haller, a clinical trial volunteer, receives the first-ever injection of an investigational vaccine for the coronavirus. Credit: Ted S. Warren / AP Photos

Kaiser Permanente launches first coronavirus vaccine trial

On March 16, 4 volunteers received an injection of an mRNA vaccine for COVID-19 in an NIH-funded trial in Seattle.

KPWHRI In the Media

NIH-Moderna COVID-19 vaccine receives FDA Emergency Use Authorization

What to expect as Moderna’s coronavirus vaccine rolls out in Washington state

Seattle Times, Dec. 18, 2020